MARIZYME (MRZM)

Monday

2:02 AM

Thesis: Concerns over rising R&D costs and competitive pressures are overshadowing the potential for positive trial results.

Revenue Outlook

Metric	FY2023	FY2024E
Revenue	$645.8K	$700.5K
Rev. Growth	+177%	+8.5%
EPS	$-1.53	—
EPS Growth	-62.8%	—
P/E	—	—

★ Analysts see FY2024 revenue reaching $700.5K — +8.5% growth in a single year.

What Moves the Stock

1FDA approval status of lead product candidate
2Partnership announcements with larger pharmaceutical firms
3Clinical trial results and data releases
4Market adoption rates of existing products
5Product sales from enzyme therapies (unknown % of total)
6Collaborative research agreements (unknown % of total)
7Increased focus on rare disease treatments
8Growing demand for innovative wound care solutions

FY2023 Snapshot

Revenue: $645.8K
Rev. Growth: +177%
Gross Margin: 37.0%
Op. Margin: -5278%
Net Margin: -10768%
Net Income: $-70M
NI Growth: -82.2%
EPS: $-1.53
1Y Return: +0.0%

MRZM Chart

My Notes

"Management indicated that while clinical results are promising, financial sustainability remains a challenge."
Moat: Marizyme's proprietary technology provides a temporary competitive edge, but it may not be sustainable against larger firms with more…
growth - Investors seeking high-risk, high-reward opportunities in the biotech sector.
High interest rates could increase the cost of capital for Marizyme, impacting its ability to fund R&D and operational expenses.
Watch on earnings: FDA approval timelines for lead product, Clinical trial enrollment rates, Partnership deal announcements.

One Sentence Summary:

Marizyme: the story is balanced — fda approval status of lead product candidate.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance